Investors

We are committed to developing
the first and only FDA-approved
TAVR solution for severe AR

Our Global Investors

Latest News

View All
Press
ALIGN-AR First 500 Patients Data
March 31, 2025
ALIGN-AR First 500 Patients Data
Read More
Press
ALIGN-AR 2-Year Follow-Up Data at TCT 2024
November 12, 2024
ALIGN-AR 2-Year Follow-Up Data at TCT 2024
Read More
Press
JenaValve Announces Publication of ALIGN-AR Pivotal Trial Results in The Lancet
March 28, 2024
JenaValve Announces Publication of ALIGN-AR Pivotal Trial Results in The Lancet
Read More